New Drug Bonanza as Chi-Med, Eisai, Alexion Harvest Big Wins In China

In a busy week for new drug approvals in China, the NMPA hands out nods for anticancers Elunate and Lenvima, rare disease treatment Soliris, and an additional indication for Humira, with Elunate being hailed by developer Chi-Med as the first fully "Made in China" novel oncology drug to receive unconditional approval.

China globe
CHINA NMPA GETS BUSY WITH NEW DRUG APPROVALS • Source: Shutterstock

Hutchison China Meditech Ltd. (Chi-Med) has scored the first approval in China of a fully domestically developed anticancer drug, with a nod for Elunate (fruquintinib) from the country's newly renamed National Medical Products Administration of China (NMPA, formerly CFDA).

The oral, highly selective small molecule inhibitor of vascular endothelial growth factor receptors 1, 2 and 3 is indicated for...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from China

More from Asia